DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Smruthi Organics Ltd (SMRUTHIORG) share price today?

Smruthi Organics Ltd (SMRUTHIORG) is trading at ₹115.05 on the BSE, down 0.04% on the day. Source: DocStoX.

What is the PE ratio of Smruthi Organics Ltd?

Smruthi Organics Ltd has a price-to-earnings (PE) ratio of 37.0 in the Healthcare sector.

What is the market capitalisation of Smruthi Organics Ltd?

Smruthi Organics Ltd has a market capitalisation of approximately ₹132 crore.

Smruthi Organics Ltd

SMRUTHIORG·BSE·Healthcare

₹115.05▼ -0.05 (-0.04%)

Healthcare · Pharmaceuticals & Biotechnology

A steady, established business

Day₹114.00

₹116.05

52W₹95

₹16429%

Open

₹114.95

High

₹116.05

Low

₹114.00

Prev Close

₹115.10

Volume

2.6K

VWAP

₹114.58

Snapshot

Key fundamentals

Market Cap

₹132 Cr

P/E Ratio

36.99Expensive

P/B Ratio

1.79

EPS

₹3.11

Book Value

₹64.23

ROE

4.97%Weak

ROCE

8.00%Weak

Dividend Yield

1.30%

Debt / Equity

0.11Low

Face Value

₹10.00

52W High

₹164.00

52W Low

₹95.00

Sector

Healthcare

Industry

Pharmaceuticals & Biotechnology

Avoid

None moatHigh uncertainty

Fair value estimate

₹51

▼ 55.7%downside

Trading at ₹115 — 56% above our estimate

BearFair valueBull

₹22₹51₹59

/100

Business quality — Watch the fundamentals

Growth 50Profitability 3Efficiency 0Valuation 64

Plain English

Our view

A steady, established business
Low debt relative to equity
Weak returns on equity (5%)

Strengths

Low debt relative to equity
Promoters hold a controlling stake

Risks

Weak returns on equity (5%)

How we got there

Fair value methods

Residual income

5% ROE fading to 12% over ~3 yrs, on ₹64 book

₹59

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹22

Analyst target

No analyst coverage

—

Blended fair value₹51

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Promoters hold a controlling stake

Bear case

Weak returns on equity (5%)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

37.0Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

5.0%Weak

Above 15% is considered healthy for Indian equities

ROCE

8.0%Weak

Above 18% means capital is working hard

Debt/Eq

0.11Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹132 Cr

P/B

1.79

EPS

₹3.11

Div Yield

1.30%

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

Expensive

P/E 37.0×

Growth

Shrinking

-10% rev CAGR

Profitability

Modest

5.0% ROE

Financial health

Rock solid

D/E 0.11

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover₹3.00L Cr

Trades24

VWAP₹114.58

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

-10.2%

-4.1%

10Y

+3.3%

Profit

-7.0%

-28.3%

10Y

+12.4%

EPS

-55.0%

-53.4%

10Y

-6.3%

Profile

Pros

Company has reduced debt.
Company has been maintaining a healthy dividend payout of 48.7%
Debtor days have improved from 93.5 to 69.1 days.

Watch-outs

Cons

The company has delivered a poor sales growth of -4.22% over past five years.
Company has a low return on equity of 5.14% over last 3 years.
Company's cost of borrowing seems high

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

65%

Promoter

Promoters

64.7%0.00

Public

28.6%-0.06

FII / FPI

0.0%0.00

DII

0.0%0.00

Others

6.6%

Total shareholders

5,959-76 QoQ

Quarterly trend

Ownership over time

Q1 FY27

Promoter64.73%

Public28.65%

Others6.62%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1989, Smruthi Organics Ltd is a manufacturer of Active Pharmaceutical Ingredients[1]